BriaCell Therapeutics Total Asset vs. Cash Flow From Operations
| BCTXW Stock | USD 0.43 0.08 22.86% |
BriaCell Therapeutics Total Assets |
|
For BriaCell Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BriaCell Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BriaCell Therapeutics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BriaCell Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BriaCell Therapeutics Corp over time as well as its relative position and ranking within its peers.
BriaCell |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BriaCell Therapeutics. If investors know BriaCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BriaCell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (1.26) | Return On Equity (2.06) |
The market value of BriaCell Therapeutics is measured differently than its book value, which is the value of BriaCell that is recorded on the company's balance sheet. Investors also form their own opinion of BriaCell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BriaCell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BriaCell Therapeutics' market value can be influenced by many factors that don't directly affect BriaCell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BriaCell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BriaCell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BriaCell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BriaCell Therapeutics Cash Flow From Operations vs. Total Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BriaCell Therapeutics's current stock value. Our valuation model uses many indicators to compare BriaCell Therapeutics value to that of its competitors to determine the firm's financial worth. BriaCell Therapeutics Corp is rated fifth in total asset category among its peers. It is rated fourth in cash flow from operations category among its peers . At this time, BriaCell Therapeutics' Total Assets are fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value BriaCell Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.BriaCell Cash Flow From Operations vs. Total Asset
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
BriaCell Therapeutics |
| = | 5.87 M |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
BriaCell Therapeutics |
| = | (24.13 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
BriaCell Cash Flow From Operations Comparison
BriaCell Therapeutics is currently under evaluation in cash flow from operations category among its peers.
BriaCell Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BriaCell Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BriaCell Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of BriaCell Therapeutics' change in net profit over the period of time. It can combine multiple indicators of BriaCell Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -124.8 K | -118.6 K | |
| Operating Income | -4.8 M | -5 M | |
| Income Before Tax | -4.8 M | -4.6 M | |
| Total Other Income Expense Net | 3.4 M | 3.6 M | |
| Net Loss | -4.9 M | -5.2 M | |
| Income Tax Expense | -175.5 K | -166.7 K | |
| Interest Income | 1 M | 1.1 M | |
| Net Loss | -4.4 M | -4.7 M | |
| Net Interest Income | 802.1 K | 842.2 K | |
| Net Loss | -18.3 M | -17.4 M | |
| Net Loss | (1.17) | (1.23) | |
| Income Quality | 4.89 | 5.14 | |
| Net Income Per E B T | 1.15 | 0.70 |
BriaCell Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BriaCell Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BriaCell Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BriaCell Therapeutics' important profitability drivers and their relationship over time.
Use BriaCell Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BriaCell Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BriaCell Therapeutics will appreciate offsetting losses from the drop in the long position's value.BriaCell Therapeutics Pair Trading
BriaCell Therapeutics Corp Pair Trading Analysis
The ability to find closely correlated positions to BriaCell Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BriaCell Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BriaCell Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BriaCell Therapeutics Corp to buy it.
The correlation of BriaCell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BriaCell Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BriaCell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BriaCell Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BriaCell Therapeutics position
In addition to having BriaCell Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Risk ETFs Thematic Idea Now
Target Risk ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for BriaCell Stock Analysis
When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.